SAFETY AND EFFICACY SUMMARIES SERVICES
BioBoston CRO provides integrated safety and efficacy summary services for sponsors that need evidence from multiple studies, datasets, reports, and analyses synthesized into a coherent regulatory narrative. Support can cover integrated planning, source and analysis coordination, complete summary development, selected sections, rescue of an existing draft, or independent review.
Global Reach
Therapeutic Area Coverage
Years of Experience
START A CONVERSATION
Select the support you need and share a few details about your project. We’ll use this information to route your inquiry to the appropriate BioBoston team member.
Please do not submit confidential, patient-identifiable, or proprietary information through this form.
The engagement should be scoped around the current state of the work, the intended decision or milestone, the source package, and the sponsor's approval responsibilities.
Plan and develop the narrative that explains the totality of approved safety, efficacy, performance, or clinical evidence across studies.
Connect analysis populations, data cutoffs, study differences, tables, figures, limitations, and interpretation before writing proceeds.
Assess source traceability, cross-study comparisons, benefit-risk logic, terminology, comments, and submission dependencies before redrafting.
when needed
Problems
The service is most valuable when the team can identify the specific control gap, decision, deliverable, or
recovery need rather than requesting generic capacity.
Scope
The exact scope depends on the maturity of the work, the quality of the inputs, the sponsor’s procedures,
the review model, and the target milestone.
Deliverables
Deliverables should be confirmed at kickoff and linked to defined sponsor decisions, review cycles, and downstream handoffs.
Client inputs
The sponsor does not need every detail finalized before kickoff, but approved decisions, open questions, source owners, reviewers, and deadlines must be distinguishable.
Process
1. Confirm the regulatory purpose, evidence scope, studies and datasets, analysis status, source owners, reviewers, target milestone, and writing role.
2. Review the integrated analysis plan and source package; create the content, source, analysis, and cross study issue maps.
3. Draft the integrated narrative in controlled sections using approved outputs, study descriptions, limitations, and sponsor interpretation.
4. Coordinate statistical, medical, safety, clinical, regulatory, and data review and route unresolved analysis or interpretation decisions to named owners.
5. Resolve comments, reconcile numbers, denominators, tables, figures, populations, terminology, and cross document changes.
6. Perform final quality checks and prepare clean, redline, approval, and publishing-handoff versions.
Considerations
The work should remain proportionate to the risk and intended use, follow the sponsor’s controlled process, and preserve clear sponsor decision authority.
Engagement options
BioBoston leads the defined scope from assessment and planning through drafting or execution, review, quality control, and handoff.
BioBoston addresses a specific section, decision, backlog, finding, vendor issue, or stalled deliverable without expanding the engagement unnecessarily.
BioBoston provides an objective second-line review, oversight role, or embedded specialist while the sponsor or another vendor retains primary execution.
RELATED SERVICES
Develop and approve the integrated analysis strategy, populations, methods, outputs, sensitivity analyses, and statistical interpretation.
Produce the complete reports and approved study-level narratives that become key sources for the integrated summary.
Define the application context, sequence, content plan, responsibilities, dependencies, and publishing milestones for the summary.
Coordinate integrated summaries with other application documents and Common Technical Document modules.
Expertise
Integrated-summary experience should match the product, application type, evidence base, number and
diversity of studies, analysis complexity, safety profile, and regulatory use.
RESOURCES
Explore the following resources for additional insights and information relevant to this service.
A planned template connecting studies, populations, data cutoffs, analyses, tables, figures, reports, sections, and review owners.
A planned checklist for exposure, populations, denominators, events, seriousness, severity, causality, discontinuations, deaths, subgroups, and limitations.
A planned guide to designs, endpoints, comparators, populations, consistency, sensitivity, subgroups, limitations, and interpretation.
FAQs
A Clinical Study Report describes one study. An integrated summary synthesizes evidence across multiple studies, datasets, reports, and analyses for a broader regulatory question or application.
Yes. The engagement may cover an integrated safety summary, integrated efficacy summary, performance or clinical-evidence summary, selected sections, rescue, or independent review if the evidence and analysis interfaces are clear.
Biostatistics is a separate service that may be coordinated with writing. The summary writer integrates approved analyses and interpretation but should not independently change populations, methods, outputs, or conclusions.
Yes. A rescue engagement should assess sources, analysis status, study groupings, data cutoffs, numbers, tables, figures, terminology, comments, limitations, and application dependencies before redrafting.
Clinical-evidence and safety/performance summary work may be scoped for medical devices or diagnostics when applicable. Device-specific document types and jurisdictional requirements must be confirmed rather than assumed from pharmaceutical terminology.
No. BioBoston can improve planning, traceability, consistency, synthesis, and reviewability, but the sponsor is responsible for its positions and authorities determine their assessment.
PROJECT FORM
Share the application context, product, studies and datasets included, analysis status, current summary stage, review team, and target milestone. A BioBoston team member will review the request and follow up regarding fit and possible next steps.
Please do not submit confidential, patient-identifiable, or proprietary information through this form.
A productive first discussion identifies the regulatory purpose, studies and datasets, analysis status, data cutoffs, current drafts, reviewers, and deadline. BioBoston can then define the integrated plan, authoring model, review controls, and statistical dependencies.
